Claim Amendments

Please amend the claims as shown below.

1. (currently amended) A plurality of lamotrigine particles having a specific surface area of from about two to about three and a half square meters per gram, wherein the diameter of all the lamotrigine particles in the plurality is equal to or less than 50 μm.

2. (original) The plurality of lamotrigine particles of claim 1 having a specific surface area of about three square meters per gram.

3-4. (canceled)

5. (currently amended) The plurality of lamotrigine particles of claim [[4]] 1 wherein the diameter of all the particles in the plurality is equal to or less than about 10 μm.

6. (currently amended) A pharmaceutical composition comprising a plurality of lamotrigine particles having a specific surface area of from about two to about three and a half square meters per gram, wherein the diameter of all the lamotrigine particles in the plurality is equal to or less than 50 μm.

7. (original) The pharmaceutical composition of claim 6 having a specific surface area of about three square meters per gram.

8-9. (canceled)

10. (currently amended) The pharmaceutical composition of claim [[9]] 6 wherein the diameter of all particles in the plurality is equal to or less than about 10 μm.

11. (original) A dosage form comprising the pharmaceutical composition of claim 6.

12. (currently amended) The dosage form of claim 11 that is a solid oral dosage form.

13. (currently amended) The solid oral dosage form of claim 12 wherein the pharmaceutical composition comprises at least one pharmaceutically acceptable excipient.

14. (currently amended) The solid oral dosage form of claim 13 wherein the at least one pharmaceutically acceptable excipient is selected from the group consisting of microcrystalline cellulose, microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, destrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylate, potassium chloride, powdered cellulose, sodium chloride, sorbitol, talc, acacia, alginic acid, carbomer, carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, liquid glucose, magnesium aluminum silicate, ~~maltodextrin,~~ methylcellulose, polymethacrylates, povidone, pregelatinized starch, sodium alginate, starch, alginic acid, carboxymethyl cellulose calcium, colloidal silicon dioxide, croscarmellose sodium, crospovidone, ~~guar gum, magnesium aluminum silicate,~~ methyl cellulose, polacrilin potassium~~, powdered cellulose, pregelatinized starch, sodium alginate~~ and sodium starch glycolate.

15. (original) The solid oral dosage form of claim 12 containing a unit dose of from about 100 to about 400 milligrams of lamotrigine.

16. (currently amended) The dosage form of claim 11 that is a liquid oral dosage form.

17. (currently amended) The liquid oral dosage form of claim 16 ~~wherein the liquid oral dosage comprises~~ comprising a liquid carrier selected from the group consisting of water, vegetable oil, alcohol, polyethylene glycol, propylene glycol and glycerin.

18. (currently amended) The liquid oral dosage form of claim 17 wherein the liquid carrier is water.

19. (currently amended) The liquid oral dosage form of claim 16 further comprising at least one excipient selected from the group consisting of gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol, cetyl alcohol, alginic acid, bentonite, carbomer, carboxymethylcellulose calcium or sodium, ethylcellulose, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth, xanthan gum, sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol, invert sugar[[;]], ethyl alcohol, sodium benzoate, butylated hydroxy toluene, butylated hydroxyanisole, ethylenediamine tetraacetic acid, ~~guconic~~ gluconic acid, lactic acid, citric acid, acetic acid, sodium gluconate ~~guconate~~, sodium lactate, sodium citrate and sodium acetate.

20. (currently amended) The dosage form of claim 11 that is a liquid parenteral dosage form.

21. (currently amended) The liquid parenteral dosage form of claim 20 further comprising a tonicity modifier.

22. (currently amended) The liquid parenteral dosage form of claim 21 wherein the tonicity modifier is dextrose.

23. (currently amended) The liquid parenteral dosage form of claim 22 wherein the dextrose is a 5% solution of dextrose.

24. (currently amended) The liquid parenteral dosage form of claim 20 further comprising at least one excipient selected from the group consisting of dextrose, glycerol, lactose, mannitol, sorbitol, acetate, citrate, tartrate, parabens, 1, 6-dialkyl substituted phenols, benzalkonium chloride, benzethonium chloride, benzyl alcohol, sodium benzoate, chlorobutanol, phenethyl alcohol, sodium bisulfite, sodium metabisulfite and tocopherol.

25. (original) A method of reducing the incidence of seizures in a patient comprising the step of administering a dosage form of any of claims 12,16 and 20.

26. (original) The method of claim 25 wherein the dosage form is administered in adjunct with another seizure inhibiting drug.